SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $41.24M |
| Net Income (Most Recent Fiscal Year) | $-400.67M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.61 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.00 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -747.63% |
| Net Margin (Trailing 12 Months) | -747.63% |
| Return on Equity (Trailing 12 Months) | -68.99% |
| Return on Assets (Trailing 12 Months) | -60.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.54 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.01 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.59 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 62.62M |
| Free Float | 59.18M |
| Market Capitalization | $408.29M |
| Average Volume (Last 20 Days) | 0.78M |
| Beta (Past 60 Months) | 0.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.22% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |